Hence, we still believe that our study cohort is of sufficient size to investigate the prognostic value of elevated B2M plasma levels in terms of OS in CKD and non-CKD Binet A stage CLL patients. The gene discussed is B2M; the disease is B-cell chronic lymphocytic leukemia.